Premedications for RYBREVANT®1

rybrevantPremedicationrybrevantPremedication
  • Prior to the initial infusion of RYBREVANT® (Week 1, Days 1 and 2), administer premedication as described in the table above to reduce the risk of IRRs
  • Administer both antihistamine and antipyretic prior to all infusions
  • Glucocorticoid administration is required for Week 1, Days 1 and 2 dose only and upon reinitiation after prolonged dose interruptions, then as necessary for subsequent infusions​
  • Interrupt infusion if IRR is suspected. Reduce the infusion rate or permanently discontinue RYBREVANT® based on severity
  • If an anaphylactic reaction occurs, permanently discontinue RYBREVANT®

Concomitant medications1

VTE prophylaxis

When initiating treatment with RYBREVANT® in combination with LAZCLUZE™, administer anticoagulant prophylaxis to prevent VTE events for the first 4 months of treatment.

  • The use of Vitamin K antagonists is not recommended
  • If there are no signs or symptoms of VTE during the first 4 months of treatment, consider discontinuation of anticoagulant prophylaxis at the discretion of the healthcare provider

Dermatologic AR prophylaxis

Consider prophylactic measures (eg, use of oral antibiotics) to reduce the risk of dermatologic ARs. When initiating treatment with RYBREVANT® in combination with LAZCLUZE™, administer alcohol-free (eg, isopropanol-free, ethanol-free) emollient cream.

Refer to the full Prescribing Information for LAZCLUZE™ for information about concomitant medications.

AR, adverse reaction; IRR, infusion-related reaction; VTE, venous thromboembolism.

Reference:

  1. RYBREVANT® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.